Description: ABIVAX is an innovative biotechnology company focused on targeting the immune system to eliminate viral and inflammatory disease.
Home Page: www.abivax.com
7-11 boulevard Haussmann
Paris,
75009
France
Phone:
33 1 53 83 09 63
Officers
| Name | Title |
|---|---|
| Mr. Marc M. P. de Garidel M.B.A. | CEO & Director |
| Dr. Philippe Pouletty M.D., Ph.D. | Founder & Director |
| Mr. Didier Blondel | EVP, CFO & Board Secretary |
| Mr. Didier Scherrer Ph.D. | Chief Scientific Officer |
| Mr. Patrick Malloy | Senior Vice President of Investor Relations |
| Ms. Ida Hatoum | Chief People & Compliance Officer |
| Mr. Pierre Courteille M.B.A. | Chief Business Officer |
| Mr. Jerome Denis Ph.D. | Executive Vice President of Process Development & Manufacturing |
| Ms. Ana Sharma M.P.H. | VP & Global Head of Quality |
| Hema Keshava | Senior Vice President of Finance |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.2903 |
| Price-to-Sales TTM: | 77.4965 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 62 |